Kiora Pharmaceuticals (Kiora Pharmaceuticals) Operating Cash Flow per Share : $-2.76 (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Kiora Pharmaceuticals Operating Cash Flow per Share?

Kiora Pharmaceuticals's operating cash flow per share for the three months ended in Dec. 2023 was $-0.34. Kiora Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.76.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 68.60% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 56.30% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 33.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Kiora Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

KPRX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -50.4 Med: 37.8 Max: 68.6
Current: 68.6

During the past 12 years, Kiora Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 68.60% per year. The lowest was -50.40% per year. And the median was 37.80% per year.

KPRX's 3-Year OCF Growth Rate is ranked better than
96.14% of 1242 companies
in the Biotechnology industry
Industry Median: 3.75 vs KPRX: 68.60

Kiora Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Kiora Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Operating Cash Flow per Share Chart

Kiora Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-101.93

-63.63

-44.30

-14.25

-1.97

Kiora Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-1.19	-1.65	-0.42	-0.36	-0.34

Competitive Comparison of Kiora Pharmaceuticals's Operating Cash Flow per Share

For the Biotechnology subindustry, Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Kiora Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Kiora Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-9.557	/	4.842
	=	-1.97

Kiora Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-2.581	/	7.706
	=	-0.33

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.76

Kiora Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiora Pharmaceuticals (Kiora Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (NAS:KPRX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

7EY0:Germany

Address

332 Encinitas Blvd, Suite 102, Encinitas, CA, USA, 92024

Website

https://www.kiorapharma.com

Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in one reportable segment operations and manages.

Executives

Carmine N. Stengone	director	10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Melissa Tosca	officer: EVP of Finance	C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105
Susan L. Drexler	officer: Interim CFO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Erin Parsons	director	97 WILLISTON RD, BROOKLINE MA 02445
David Hollander	director	C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Brian M. Strem	director, officer: President and CEO	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Eric Joseph Daniels	officer: Chief Development Officer	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Armistice Capital Master Fund Ltd.	director, 10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Aron Shapiro	director	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Kenneth L Gayron	director	75 NETWORK DRIVE, BURLINGTON MA 34212
Franz Obermayr	officer: Acting CEO	C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452
Bernard Malfroy-camine	director	C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110
Thomas Hancock	director	C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110